Renaissance Technologies LLC Purchases New Stake in Vor Biopharma Inc. $VOR

Renaissance Technologies LLC purchased a new stake in shares of Vor Biopharma Inc. (NASDAQ:VOR) in the first quarter, Holdings Channel reports. The firm purchased 128,839 shares of the company’s stock, valued at approximately $2,298,000.

Other institutional investors have also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. acquired a new position in shares of Vor Biopharma during the fourth quarter valued at about $36,000. Goldman Sachs Group Inc. lifted its position in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new position in Vor Biopharma in the 2nd quarter valued at about $66,000. Chung Wu Investment Group LLC acquired a new position in Vor Biopharma during the 4th quarter valued at about $109,000. Finally, Susquehanna Portfolio Strategies LLC acquired a new position in Vor Biopharma during the 4th quarter valued at about $134,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Jefferies Financial Group raised Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wedbush upped their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. HC Wainwright reissued a “buy” rating and issued a $31.00 price target on shares of Vor Biopharma in a research report on Monday, May 18th. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of Vor Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $42.25.

Vor Biopharma Trading Down 1.3%

Vor Biopharma stock opened at $23.37 on Tuesday. Vor Biopharma Inc. has a 12 month low of $6.50 and a 12 month high of $50.20. The business’s 50 day simple moving average is $17.80 and its 200 day simple moving average is $15.84.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Monday, March 30th. The company reported $307.61 earnings per share (EPS) for the quarter. Sell-side analysts expect that Vor Biopharma Inc. will post -2.51 earnings per share for the current fiscal year.

Vor Biopharma Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).